Evaluation of a novel computer-based test for early detection of Alzheimer's

评估一种基于计算机的新型阿尔茨海默病早期检测测试

• 批准号: 8715505
• 负责人: MICHAEL NMN DAVIS
• 金额: $ 22.53万
• 依托单位: NEUROTRACK TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-15 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8715505
• 关键词: Address; Affect; Algorithms; Alzheimer disease detection; Alzheimer' s Disease; American; Area; Behavioral; Behavioral Assay; Biological Assay; Brain region; Cerebrospinal Fluid; Clinical; Clinical Trials; Cognitive; Computer software; Computers; Data Analyses; Detection; Development; Diagnosis; Diagnostic; Disease; Disease Progression; Early Diagnosis; Elderly; Enrollment; Ensure; Evaluation; Eye; Feasibility Studies; Focus Groups; Funding; Generations; Goals; Hippocampus (Brain); Home environment; Human; Impaired cognition; Individual; Investigation; Licensing; Longitudinal Studies; Measures; Memory; Memory impairment; Methods; Metric; Multi-Institutional Clinical Trial; Nervous system structure; Onset of illness; Paired Comparison; Paper; Patient Recruitments; Patients; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Physicians; Population; Preparation; Process; Publishing; Recommendation; Recruitment Activity; Relative (related person); Reporting; Research; Research Infrastructure; Research Personnel; Risk; Scientist; Small Business Innovation Research Grant; Solutions; Speed; Staging; Symptoms; System; Technology; Testing; Therapeutic; Time; United States National Institutes of Health; Universities; Visual; base; behavior test; clinical Diagnosis; clinical research site; computerized; data management; design; drug development; drug discovery; drug efficacy; healthy aging; impression; improved; innovation; laptop; meetings; memory recognition; mild cognitive impairment; neuroimaging; nonhuman primate; novel; prototype; public health relevance; tool; usability; visual performance

DESCRIPTION (provided by applicant): Alzheimer's disease currently affects an estimated 5.4 million Americans, and this number is expected to grow significantly in the coming decade. A critical and ultimate goal of Alzheimer's disease research is to improve methods of early diagnosis, so that patients can be identified sooner and, therefore, obtain greater advantage from available therapies. A second critical and more immediate goal is to develop better ways to detect individuals who are at risk or who are already on the trajectory for Alzheimer's but have not yet developed clinical symptoms, so that pharmaceutical companies and researchers can populate their clinical trials with appropriate individuals. A lack of early markers or predictors f impending disease represents a significant roadblock in the ability to develop new drugs that might treat or even cure Alzheimer's disease. Neurotrack Technologies, Inc. is a Palo Alto CA-based startup formed around a suite of behavioral and software technologies designed to facilitate the detection and prediction of Alzheimer's both at home and in the clinical setting. Th centerpiece of Neurotrack is a behavioral assay that uses eye-tracking technology along with data analysis algorithms to assess recognition memory. It is based on decades of research in nonhuman primates and in human amnesic patients by scientists and physicians at Emory University, who have developed a behavioral task that is highly sensitive to memory impairment and which has shown promise both in the early diagnosis of Alzheimer's disease and in the ability to predict the onset of Alzheimer's disease several years before clinical symptoms occur. Our behavioral test assesses recognition memory, a form of memory that critically depends on the integrity of the hippocampal region of the brain, one of the first areas to undergo morphological change in the course of Alzheimer's. Published results from our 5-year NIH-funded longitudinal study revealed that performance on this test was highly accurate in predicting cognitive decline. Neurotrack's technology has the potential to give pharmaceutical companies and research organizations the tools they need to recruit truly appropriate candidates for clinical trials and more effectively measure drug efficacy, speeding up drug discovery and development. This proposal consists of three aims: 1) to develop and optimize a commercial prototype for administering our test, 2) to beta test and refine this prototype with a small group of patients, and 3) to conduct an initial feasibility study comparing our new commercial version of the test to the established predictive assays currently available to researchers and clinicians. These improvements will advance the technology into a viable first generation commercial prototype in preparation for a large, multi-site clinical trial.

描述(由申请者提供)：阿尔茨海默氏症目前影响着大约540万美国人，这个数字预计在未来十年将显著增长。阿尔茨海默病研究的一个关键和最终目标是改进早期诊断方法，以便能够更早地识别患者，从而从现有的治疗方法中获得更大的优势。第二个更关键、更紧迫的目标是开发更好的方法来检测那些面临阿尔茨海默氏症风险或已经处于阿尔茨海默氏症轨道上但尚未出现临床症状的人，这样制药公司和研究人员就可以用合适的人来填充他们的临床试验。缺乏对即将到来的疾病的早期标记或预测，是开发可能治疗甚至治愈阿尔茨海默氏症的新药的能力的重大障碍。NeuroTrack技术公司是一家总部位于加利福尼亚州帕洛阿尔托的初创公司，围绕一套行为和软件技术成立，旨在促进在家庭和临床环境中检测和预测阿尔茨海默氏症。NeuroTrack的核心是一种行为测试，它使用眼球跟踪技术和数据分析算法来评估识别记忆。它是基于埃默里大学的科学家和医生对非人类灵长类动物和人类健忘症患者进行的数十年研究，他们开发了一种对记忆损伤高度敏感的行为任务，在阿尔茨海默病的早期诊断和在临床症状出现前几年预测阿尔茨海默病发病的能力方面都显示出了希望。我们的行为测试评估识别记忆，这是一种记忆形式，严重依赖于大脑海马区的完整性，海马区是阿尔茨海默氏症病程中最早经历形态变化的区域之一。我们由美国国立卫生研究院资助的为期5年的纵向研究发表的结果显示，这项测试的表现在预测认知能力下降方面具有很高的准确性。NeuroTrack的技术有可能为制药公司和研究机构提供所需的工具，为临床试验招募真正合适的候选人，并更有效地衡量药物疗效，加快药物发现和开发。这项建议包括三个目标：1)开发和优化用于实施我们的测试的商业原型，2)在一小群患者中进行Beta测试和改进该原型，以及3)进行初步的可行性研究，将我们新的商业版本的测试与目前研究人员和临床医生可用的已建立的预测分析进行比较。这些改进将把这项技术推进到可行的第一代商业原型，为大型、多地点的临床试验做准备。